We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $1.74 · 6 analysts
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Flat for Week
MREO Stock Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
MREO Stock Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) ChartMill
European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading
Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026 - marketscreener.com
Mereo Biopharma Group plc Announces Termination of Dr Annalisa Jenkins from Director, Effective May 14, 2026 marketscreener.com
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | After market close (AMC) | $-0.01 | — | — | $863.83K | — | Scheduled |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-0.02 | — | — | $0 | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-0.03 | — | — | $0 | Reported |
| FY2024 Q3 | 2023. 09. 30. | Time TBD | — | $-0.03 | — | — | $9M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 12. | BTIG | — | Maintain | Buy → Buy | — | BTIG: Buy |
| 2026. 03. 23. | JP Morgan | — | Downgrade | Overweight → Neutral | — | JP Morgan: Overweight → Neutral |
Compare a firm's past rating changes and its actions on other stocks in the same sector.
As of FY2026Q1 · Source: SEC/DART + price data
Filings, earnings, and institutional changes summarized in one paragraph, with source links.
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 525,125 | $218.82M | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 187,839 | $61.99M | 0.00% | — | New position |
See new positions, full exits, and weight changes.